Print | Email Page

NGM Biopharmaceuticals completes $107M IPO

April 2019

Jones Day served as IP counsel in connection with the $107 million initial public offering of NGM Biopharmaceuticals, Inc. (NASDAQ: NGM). NGM is a clinical stage biopharmaceutical company focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases.

For additional information about this matter, please contact: Tamera M. Weisser Ph.D.

Client(s): NGM Biopharmaceuticals, Inc.
Office(s): San Diego